Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit

Waters Corporation (NYSE:WAT) shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV Self-Collection Kit, a significant step in expanding access to cervical cancer screening.

• Waters stock is showing exceptional strength. What’s fueling WAT momentum?

Automated Processing and Clinical Validation

The U.S. Food and Drug Administration (FDA) on Wednesday cleared the Onclarity HPV Self-Collection Kit for at-home use, which is expected to enhance cervical cancer screening accessibility.

The kit, tested with the BD Onclarity HPV Assay, is the most comprehensive HPV screening tool available in the U.S., aiming to improve early detection and reduce cervical cancer deaths.

The company said the kit tested with the BD Onclarity HPV Assay can detect all of the high-risk, carcinogenic genotypes of HPV.

It is the only FDA-approved HPV assay to identify six individual and three groups of pooled results.

Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes.

Waters collaborated with the National Institutes of Health’s (NIH) National Cancer Institute (NCI) through the Cervical Cancer “Last Mile” Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing.

The broader market saw gains, with the S&P 500 up 2.14% today. Waters Corp’s rise aligns with this positive trend, indicating that the stock is benefiting from favorable market conditions.

Technical Levels Signal Mixed Near-Term Outlook

At $320.42, the stock is trading 6.5% above its 20-day simple moving average (SMA) of $297.51, suggesting a bullish short-term trend.

However, it is trading 2.1% below its 50-day SMA of $323.59, indicating some resistance at this level, which could be a point of interest for traders.

The stock’s relative strength index (RSI) is at 49.75, reflecting a neutral momentum, suggesting that there is no immediate overbought or oversold condition.

This positioning indicates that the stock could either consolidate or find direction based on upcoming catalysts.

• Key Resistance: $323.50 — This level may act as a barrier for upward movement.
• Key Support: $305.50 — A drop below this level could indicate bearish sentiment.

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Waters, highlighting its strengths and weaknesses compared to the broader market:

• Value: 6.31 — Indicates a moderate valuation relative to peers.
• Growth: 98.7 — Suggests strong growth potential.
• Quality: 96.05 — Reflects high-quality metrics in operations.
• Momentum: 15.57 — Indicates weak momentum compared to the market.

The Verdict: Waters’s Benzinga Edge signal reveals a growth-heavy profile, although momentum is currently weak, suggesting that while the company has strong fundamentals, it may face challenges in gaining traction in the short term.

Top ETF Exposure

• Invesco Water Resources ETF (NASDAQ:PHO): 5.91% Weight
• First Trust Water ETF (NYSE:FIW): 4.33% Weight
• First Trust Indxx Medical Devices ETF (NASDAQ:MDEV): 2.33% Weight

WAT Stock Price Activity: Waters shares were up 3.19% at $317.32 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo via Shutterstock